TOP1 and breast cancer: Always in the setting of metastatic BC (the study included different BC subtypes), the PROCEED phase III trial by Park et al. compared the combination therapy with capecitabine and irinotecan (a topoisomerase1, Top1, pro-drug inhibitor) to capecitabine alone in HER2-negative BC.